BlackRock Inc. Has $149,000 Holdings in Opiant Pharmaceuticals Inc (OPNT)

BlackRock Inc. raised its stake in Opiant Pharmaceuticals Inc (NASDAQ:OPNT) by 44.0% during the 4th quarter, Holdings Channel reports. The firm owned 10,259 shares of the technology company’s stock after buying an additional 3,137 shares during the quarter. BlackRock Inc.’s holdings in Opiant Pharmaceuticals were worth $149,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Brasada Capital Management LP grew its stake in Opiant Pharmaceuticals by 36.0% in the fourth quarter. Brasada Capital Management LP now owns 20,400 shares of the technology company’s stock valued at $295,000 after purchasing an additional 5,400 shares during the last quarter. Vanguard Group Inc. grew its stake in Opiant Pharmaceuticals by 25.1% in the third quarter. Vanguard Group Inc. now owns 105,432 shares of the technology company’s stock valued at $1,883,000 after purchasing an additional 21,151 shares during the last quarter. Vanguard Group Inc grew its stake in Opiant Pharmaceuticals by 25.1% in the third quarter. Vanguard Group Inc now owns 105,432 shares of the technology company’s stock valued at $1,883,000 after purchasing an additional 21,151 shares during the last quarter. Finally, Essex Investment Management Co. LLC purchased a new position in Opiant Pharmaceuticals in the fourth quarter valued at about $722,000. Institutional investors own 19.59% of the company’s stock.

OPNT opened at $11.27 on Monday. Opiant Pharmaceuticals Inc has a 1 year low of $10.58 and a 1 year high of $29.55. The stock has a market capitalization of $44.24 million, a price-to-earnings ratio of -1.59 and a beta of 0.37.

Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its earnings results on Thursday, March 21st. The technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.29). Opiant Pharmaceuticals had a negative net margin of 93.66% and a negative return on equity of 93.00%. The company had revenue of $4.76 million during the quarter, compared to analysts’ expectations of $5.20 million. As a group, equities research analysts expect that Opiant Pharmaceuticals Inc will post -0.38 EPS for the current fiscal year.

Separately, ValuEngine lowered Opiant Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, February 5th.

In other Opiant Pharmaceuticals news, CEO Roger Crystal sold 21,227 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $12.00, for a total value of $254,724.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Phil Skolnick sold 10,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $14.95, for a total value of $149,500.00. The disclosure for this sale can be found here. Insiders sold 80,000 shares of company stock worth $990,863 in the last quarter. 30.88% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “BlackRock Inc. Has $149,000 Holdings in Opiant Pharmaceuticals Inc (OPNT)” was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.com-unik.info/2019/05/06/blackrock-inc-has-149000-holdings-in-opiant-pharmaceuticals-inc-opnt.html.

Opiant Pharmaceuticals Profile

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Recommended Story: How to read a candlestick chart

Want to see what other hedge funds are holding OPNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opiant Pharmaceuticals Inc (NASDAQ:OPNT).

Institutional Ownership by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit